GlobeNewswire by notified

XBP Europe Awarded a Transformation Project for His Majesty’s Passport Office (HMPO)

Share

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- XBP Europe (“XBP Europe” or the “Company”) (NASDAQ: XBP and XBPEW), today announced that the Company has been selected by His Majesty’s Passport Office (“HMPO”) as its technology and services partner on a nationwide project, which aims to make documents dating back to 1837 digitally available to the General Register Office (“GRO”). This multi-year contract in the UK has an approximate total contract value of $40 million.

A duty to the public
The GRO, part of HMPO, maintains the national archive of births, marriages and deaths for England and Wales. This project is one strand of a wider transformation programme for GRO to update its systems and services.

With some records dating back to 1837, the GRO faces significant document quality issues, which complicates the process of making them digital. Varied record formats must be handled, paper records are often faded, and microfilm can be of poor quality.

The solution
XBP Europe will use its hyper automation AI led IDP platform and XBP Europe Global Centre of Excellence to transform how these records are shared and stored. This will help the GRO to keep pace with new smart technologies.

The Company will provide a bespoke solution to scan and transcribe Civil Registration records for England & Wales. Alongside helping to transform business processes and provide new tools and resources, XBP Europe will support the implementation of this solution.

Andrej Jonovic, CEO of XBP Europe, stated, “We are honoured to work alongside HMPO, helping the authority meet its objectives and support its transformation delivery programme. We believe this transformation project will tangibly enhance the service HMPO provides to the public.”

The plan is for the project to go live by the summer of 2024, resulting in the delivery of a cloud-based solution and services, with all data residing in the UK.

About XBP Europe
XBP Europe is a pan-European integrator of bills, payments and related solutions and services seeking to enable digital transformation of its clients. The company’s name – ‘XBP’ – stands for ‘exchange for bills and payments’ and reflects the company’s strategy to connect buyers and suppliers, across industries, including banking, healthcare, insurance, utilities and the public sector, to optimise clients’ bills and payments and related digitisation processes. The Company provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and services partner for its clients. Its cloud-based structure enables it to deploy its solutions across the European market, along with the Middle East and Africa. The physical footprint of XBP Europe spans 15 countries and 32 locations and a team of approximately 1,500 individuals. XBP Europe believes its business ultimately advances digital transformation, improves market wide liquidity by expediting payments, and encourages sustainable business practices. For more information, please visit: http://www.xbpeurope.com

This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act, including certain financial forecasts and projections. All statements other than statements of historical fact contained in this press release, including statements as to future results of operations and financial position, revenue and other metrics planned products and services, business strategy and plans, objectives of management for future operations of XBP Europe, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by XBP Europe and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against XBP Europe or others and any definitive agreements with respect thereto; (2) the inability to meet the continued listing standards of Nasdaq or another securities exchange; (3) the risk that the business combination disrupts current plans and operations of XBP Europe and its subsidiaries; (4) the inability to recognise the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of XBP Europe and its subsidiaries to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (5) costs related to the business combination; (6) changes in applicable laws or regulations; (7) the possibility that XBP Europe or any of its subsidiaries may be adversely affected by other economic, business and/or competitive factors; (8) risks related to XBP Europe’s potential inability to achieve or maintain profitability and generate cash; (9) the impact of the COVID-19 pandemic, including any mutations or variants thereof, and its effect on business and financial conditions; (10) volatility in the markets caused by geopolitical and economic factors; (11) the ability of XBP Europe to retain existing clients; (12) the potential inability of XBP Europe to manage growth effectively; (13) the ability to recruit, train and retain qualified personnel, and (14) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, definitive proxy statement filed on August 4, 2023, final prospectus filed on November 29, 2023, and other documents filed by CF VIII or that will be filed by XBP Europe from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are made. XBP Europe gives no assurance that either XBP Europe or any of its subsidiaries will achieve its expected results. XBP Europe undertakes no duty to update these forward-looking statements, except as otherwise required by law.

For more XBP Europe news, commentary, and industry perspectives, visit: https://www.xbpeurope.com/

And please follow us on social:
X: https://X.com/XBPEurope
LinkedIn: https://www.linkedin.com/company/xbp-europe/

The information posted on XBP Europe’s website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in XBP Europe should monitor XBP Europe’s website and its social media accounts in addition to XBP Europe’s press releases, SEC filings and public conference calls and webcasts.

Contact:
investors@xbpeurope.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Suspended trading due to national holiday17.5.2024 08:01:00 CEST | Press release

Lysaker, 17 May 2024 The below funds are suspended from the live trading on Nasdaq Copenhagen for Friday 17th May due to national holiday in Norway. As noted in the Financial Calender, the funds may not be available for trading on 1st May and 17th May due to official holidays affecting the Management Company's staffing. The share classes will resume trading on Tuesday 21st May. Regards Storebrand Asset Management AS Contacts: Kim Toftegaard Andreassen, Director, Kim.Toftegaard.Andreassen@storebrand.com Frode Aasen, Product Manager, fdc@storebrand.com Fund name and share classSymbolISINSKAGEN Focus ASKIFOANO0010735129SKAGEN Global ASKIGLONO0008004009SKAGEN Kon-Tiki ASKIKONNO0010140502SKAGEN m2 ASKIM2NO0010657356SKAGEN Vekst ASKIVEKNO0008000445Storebrand Indeks – Alle Markeder A5STIIAMNO0010841588Storebrand Indeks – Nye Markeder A5STIINMNO0010841570Storebrand Global ESG Plus A5STIGEPNO0010841604Storebrand Global Solutions A5STIGSNO0010841612Storebrand Global Multifactor A5STIGMNO00108415

QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency17.5.2024 08:00:00 CEST | Press release

STOCKHOLM, Sweden, May 17, 2024 (GLOBE NEWSWIRE) -- QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to the market. The GMP Certificates and Manufacturing Permits cover medicinal and investigational medicinal products for both human and veterinary use. GMP regulations are formal standards established by regulatory bodies worldwide to ensure the quality, safety, and efficacy of pharmaceutical products. Manufacturing Permits for Independent Quality Control Laboratories are granted by the Swedish regulatory authority since January 2024 to laboratories that conduct tests directly impacting the releas

Teckningskurs för nyttjande av teckningsoptioner av serie TO7 i Terranet AB har fastställts till 0,073 SEK per aktie av serie B. Teckningsperioden inleds på måndag, den 20 maj 2024.17.5.2024 08:00:00 CEST | Pressemelding

Terranet AB (publ) (”Terranet” eller ”Bolaget”) emitterade 182 664 660 teckningsoptioner av serie TO7 i samband med Bolagets företrädesemission under det andra kvartalet 2023. Varje teckningsoption ger rätt att teckna en (1) ny B-aktie i Bolaget. Teckningskursen för teckningsoptionerna av serie TO7 ska fastställas till 70 procent av den volymvägda genomsnittskursen i Bolagets aktie på Nasdaq First North Premier Growth Market under mätperioden från och med den 2 maj 2024 till och med den 16 maj 2024, dock inte lägre än kvotvärdet för Bolagets aktier och inte högre än 0,27 SEK per aktie. Den volymvägda genomsnittskursen i Bolagets aktie uppgick under mätperioden till 0,104 SEK och således har teckningskursen fastställts till 0,073 SEK. Investerat belopp avrundas uppåt till två decimaler. Teckning av aktier med stöd av teckningsoptioner av serie TO7 pågår från och med den 20 maj 2024 till och med den 3 juni 2024. Fullständiga villkor för teckningsoptionerna finns att tillgå på Bolagets we

The subscription price for exercise of warrants of series TO7 in Terranet AB has been set to SEK 0.073 per share of series B. The exercise period begins on Monday, May 20, 2024.17.5.2024 08:00:00 CEST | Press release

Terranet AB (publ) (” Terranet” or the” Company”) issued 182 664 660 warrants of series TO7 in connection with the Company’s rights issue in the second quarter of 2023. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO7 shall correspond to 70 percent of the volume weighted average price of the Company´s share on Nasdaq First North Premier Growth Market during the measurement period from and including the May 2, 2024, up until and including the May 16, 2024. However, not lower than the nominal value of the Company's share, and not higher than SEK 0.27 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.104. Thus, the subscription price has been determined to SEK 0.073. The invested amount must be rounded up to two decimals. The exercise period for warrants of series TO7 runs from May 20, 2024, up until an

First quarter 2024 results: SCOR starts 2024 with a strong first three-months net income of EUR 196 million17.5.2024 07:30:54 CEST | Press release

Press release 17 May 2024 - N° 07 First quarter 2024 results SCOR starts 2024 with a strong first three-months net income of EUR 196 million Group net income of EUR 196 million in Q1 2024 (EUR 176 million adjusted1) Group Economic Value2 under IFRS 17 of EUR 9.6 billion as of 31 March 2024, up +4.8%3 (+4.1% at constant economics3,4) compared with 31 December 2023, implying an Economic Value per share of EUR 54 (vs. EUR 51 as of 31 December 2023) Estimated Group solvency ratio of 215%5 as of 31 March 2024Annualized Return on Equity of 17.3% (15.5% adjusted1) in Q1 2024 Insurance revenue of EUR 4,113 million in Q1 2024 (+6.0%6 compared to Q1 2023)P&C combined ratio of 87.1% in Q1 2024 (+1.9pts compared to Q1 2023)L&H insurance service result7 of EUR 72 million in Q1 2024 (EUR -200 million compared to Q1 2023) Investments regular income yield of 3.5% in Q1 2024 (+0.7pts compared to Q1 2023) SCOR SE’s Board of Directors met on 16 May 2024, under the chairmanship of Fabrice Brégier, to appr

HiddenA line styled icon from Orion Icon Library.Eye